IBI-133 / Innovent Biologics - LARVOL DELTA

A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours (clinicaltrials.gov) - P1/2 | N=19 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Recruiting ➔ Completed | N=120 ➔ 19 | Trial completion date: Dec 2026 ➔ Feb 2025 | Trial primary completion date: Dec 2025 ➔ Feb 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Solid Tumor

Innovent's 6th ADC approved for clinical trials in China [Google translation] (Sohu.com) - "On April 15, according to the CDE official website, the IBI133 clinical trial application submitted by Innovent received implicit permission (acceptance number: CXSL2400085)....IBI133 is a HER3 ADC that has launched a Phase I/II clinical trial in Australia in December last year for patients with solid tumors (registration number: NCT06170190). In China, its clinical trial application was accepted by CDE in February and approved today."

New trial • Trial status • Oncology • Solid Tumor

A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Innovent Biologics (01801) HER3 ADC reports for clinical trials in China [Google translation] (Investing.com) - "Zhitong Finance APP learned that on February 2, according to the CDE official website, Innovent Biologics (01801) IBI133 applied for clinical trials for the first time in China. It is reported that IBI133 is a HER3 ADC developed by Innovent Biologics."

New trial • Oncology • Solid Tumor

A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

New P1/2 trial • Oncology • Solid Tumor